Document is current
Any future updates will be listed below
-
Authors
Pias, Tanmoy Sarkar
Afrose, Sharmin
Tuli, Moon Das
Trisha, Ipsita Hamid
Deng, Xinwei
Nemeroff, Charles B.
Yao, Danfeng Daphne https://orcid.org/0000-0001-8969-2792
- License Information
-
More Information
Article History
Received: 11 June 2024
Accepted: 17 February 2025
First Online: 11 March 2025
Competing interests
: C.B.N. is supported by the National Institutes of Health, the National Institute of Mental Health, and the National Institute of Alcohol Abuse and Alcoholism. Charles Nemeroff is a consultant for ANeuroTech (division Anima BV), Janssen Research and Development, BioXcel Therapeutics, Engrail Therapeutics, Clexio Biosciences LTD, EmbarkNeuro, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, LUCY Scientific Discovery, Relmada Therapeutics, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Skyland Trails, Denovo Biopharma, Alvogen, Acadia Pharmaceuticals, Inc., and the Brain & Behavior Research Foundation; owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2); owns stock in Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics, Signant Health, Galen Mental Health LLC, and Senseye Inc. The remaining authors declare no competing interests.
